摘要
目的:探讨R-CHOP与CHOEP两种方案治疗弥漫大B细胞淋巴瘤(DLBCL)的疗效,比较无进展生存期(PFS)和总生存期(OS)。方法:采用同期(2006-01～2012-06)非随机对照的方法,将73例DLBCL患者分为2组,39例患者接受R-CHOP方案治疗4～6疗程,34例患者接受CHOEP方案4～6疗程。结果:R-CHOP组39例患者中16例获完全缓解(CR),12例获部分缓解(PR),总有效率(CR+PR)为71.8%(28/39);CHOEP组34例,CR 12例,PR 11例,总有效率(CR+PR)67.6%(23/34);R-CHOP组CR+PR率高于CHOEP组,但差异无统计学意义(P>0.05)。单因素分析发现,CR及PR率与临床分期、LDH水平、B细胞来源(GCB型,Non-GCB型)及有无大包块病变有关(均P<0.05)。中位随访时间28个月,R-CHOP方案治疗后患者28个月的PFS和OS分别为(54.8±5.2)%和(65.4±5.7)%;CHOEP组分别为(47.6±4.5)%和(53.3±4.9)%;两组PFS和OS比较差异有统计学意义(P<0.05)。结论:与CHOEP方案相比,利妥昔单抗联合CHOP方案能够提高弥漫大B细胞淋巴瘤患者的无进展生存期及总生存期,而不良反应未见增加。
Objective ：To compare the effect,progression - free survival（PFS） and overall survival（OS） of ritux-imab combined with cyclophosphamide, hydrochloride, vincristine, prednisone chemotherapy （ R - CHOP ） and CHOP combined with VP-16 regimen（CHOEP） on patients with diffuse large B-cell lymphoma. Methods： A total of 73 patients with diffuse large B-cell lymphoma（DLBCL） were non- randomly divided into two groups：39 patients were treated with R - CHOP regimen for 4 - 6 cycles, the others treated with CHOEP regimen for 4 - 6 cycles. Results： In R - CHOP groups, 14 complete response（CR） and 12 partial response（PR） were observed, the total response rate （ CR ＋ PR） was 71.8 % （28/39）. In CHOEP groups, 12 complete response （CR） and 11 partial response（PR） were observed,the total response rate （CR ＋ PR）was 67.6% （23/34）. The rate of CR ＋ PR was higher in R - CHOP group than that in CHOP ＋ E group（71.8% vs 67.6% ） ,but no statistical difference was found between the two groups（ P 〉 0.05 ）. Minewhile we found that the clinical stage, LDH levels, origin of B - cell（ GCB or Non -GCB）and bulky disease could affect the therapeutic effect with univariate analysis（P 〈 0.05 ）. A median follow - up of 28 - mouth of PFS and OS ： R - CHOP group were （54.8 ± 5.2 ） % and （ 65.4 ± 5.7 ） % , CHOEP group were （47.6 ± 4.5 ） % and （ 53.3 ± 4.9 ） %, respectively. There were significant differences between PFS and OS in the two groups（P 〈0.05 ）. Conclusion： The combination of rituximab to the CHOP regimen significant-ly prolongs PFS and OS in patients with diffuse large B - cell lymphoma without significant increase of toxicity.
出处
《西北国防医学杂志》
CAS
2013年第3期224-226,共3页
Medical Journal of National Defending Forces in Northwest China
